股票代码：002788 股票简称：鹭燕医药 鹭燕医药股份有限公司投资者关系活动记录表 编号：2023-004 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系活动类 □新闻发布会 □路演活动 别 □现场参观 □其他 （请文字说明其他活动内容） 线上参与公司 2022 年年度报告网上业绩说明会的投资 活动参与人员 者 2023年 04 月21 日（星期五）下午15:00-17:00 时间 “鹭燕医药投资者关系”微信小程序 地点 网络远程交流 形式 董事长兼总经理：吴金祥先生 董事、副总经理兼财务总监：杨聪金女士 上市公司接待人员 独立董事：叶少琴女士 姓名 董事会办公室主任兼董事会秘书：叶泉青先生 1、问：2022 年度净利润相较于2021 年增幅明显，请问 原因是什么？ 答：2022 年，公司紧紧围绕“631”发展战略和年度工作 ...

证券代码：002788 证券简称：鹭燕医药 公告编号：2023-031 鹭燕医药股份有限公司 第五届董事会第十五次会议决议公告 （一）《鹭燕医药股份有限公司第五届董事会第十五次会议决议》。 特此公告。 鹭燕医药股份有限公司董事会 2023 年 9 月 12 日 鹭燕医药股份有限公司（以下简称"公司"）于 2023 年 9 月 8 日以邮件形式发出第五届 董事会第十五次会议（以下简称"董事会"）通知，会议于 2023 年 9 月 11 日以现场与通讯 相结合的方式举行；本次会议由董事长吴金祥先生召集和主持；出席本次会议的董事共 7 人，占公司董事总数的 100%；公司全体监事列席会议。本次会议的召集和召开程序符合《公 司法》和《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议《关于增资海南鹭燕医药有限公司的议案》； 表决结果：以同意 7 票、反对 0 票、弃权 0 票、回避 0 票通过议案，同意票数占全体有 表决权票数比例 100%。 《鹭燕医药股份有限公司关于增资子公司的公告》与本决议同日于《证券日报》《证券 时报》《中国证券报》及巨潮资讯网（www.cninfo.com.cn）上公告。 三、备查文 ...

证券代码：002788 证券简称：鹭燕医药 公告编号：2023-032 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、本次增加投资概述 （一）鹭燕医药股份有限公司（以下简称"公司"）控股子公司海南鹭燕医药有限公司 （以下简称"海南鹭燕"）因经营发展及鹭燕医药海南总部基地项目建设需要，注册资本拟 由人民币 3500 万元增至人民币 1 亿元。 公司于 2023 年 9 月 11 日召开第五届董事会第十五次会议，审议通过了《关于增资海 南鹭燕医药有限公司的议案》。公司董事会同意公司与海南鹭燕其他股东同比对海南鹭燕增 资。其中：公司（持有海南鹭燕 90%股权）以现金增资人民币 5850 万元；海南让三尺科贸 有限公司（持有海南鹭燕 4%股权）以现金增资人民币 260 万元；海南国康未来健康产业管 理集团有限公司（持有海南鹭燕 3%股权）以现金增资人民币 195 万元；海南祺泽一生科贸 有限公司（持有海南鹭燕 3%股权）以现金增资人民币 195 万元。 （二）本次增资事项属于公司董事会审议权限范围内，无需提交公司股东大会审议。 （三）本次增资事项不构成关联交易。 ...

证券代码：002788 证券简称：鹭燕医药 公告编号：2023-030 鹭燕医药股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 | | | 担 | | | 实际发生日 | 担保协议金 | 实际担保 | | 担 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序 | 公司持股 | 保 | 被担 | 债权人 | （协议签署 | 额 | 余额 | 担保的主债权期间 | 保 | | 号 | 比例 | | 保人 | | | | | | 方 | | | | 人 | | | 日） | （万元） | （万元） | | 式 | | | | | 四川 | 诺和诺德 | | | | | 保 | | | | | 鹭燕 | | | | | | | | | | | | （中国） | | | | | 证 | | 1 | 100% | | 医药 | 制药有限 | 2023.01.01 | 660.00 | 207.60 | 2023.01.01-2023.12.3 ...

证券代码：002788 证券简称：鹭燕医药 公告编号：2023-029 鹭燕医药股份有限公司 关于子公司取得建设用地使用权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、交易概述 鹭燕医药股份有限公司（以下简称"公司"）于 2023 年 3 月 10 日召开公司第五届董事 会第十二次会议，审议通过了《关于投资设立子公司的议案》，同意公司与全资子公司香港 嘉文洋行（GOODMAN MEDICAL SUPPLIES LIMITED）共同投资设立"鹭燕嘉文（厦门）投资发 展有限公司"（以下简称"鹭燕嘉文"），并同意鹭燕嘉文在厦门市翔安区以公开竞买方式取 得土地使用权。具体内容请参见公司于 2023 年 3 月 11 日刊登在《中国证券报》《证券时报》 《证券日报》及巨潮资讯网（www.cninfo.com.cn）上的《关于投资设立子公司的公告》（公 告编号：2023-002）。 2023 年 8 月 21 日，鹭燕嘉文以人民币 15,800 万元竞得福建省厦门市翔安区编号 2023XG01 地块的国有建设用地使用权，并与厦门市自然资源和规划局签订了《成交 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥10,024,249,628.07, representing a 7.32% increase compared to ¥9,340,896,235.85 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥189,013,659.46, up 12.00% from ¥168,764,960.24 year-on-year[18]. - The net cash flow from operating activities surged to ¥421,976,736.58, a significant increase of 2,188.99% compared to ¥18,435,029.72 in the previous year[18]. - The basic earnings per share rose to ¥0.49, reflecting a 13.95% increase from ¥0.43 in the same period last year[18]. - Total assets at the end of the reporting period were ¥11,482,301,358.41, down 2.56% from ¥11,783,796,364.82 at the end of the previous year[18]. - The net assets attributable to shareholders increased by 2.72% to ¥2,794,777,812.97 from ¥2,720,812,852.98 at the end of the previous year[18]. - The company reported a significant increase in net profit from recurring operations, which was ¥180,266,833.47, an 8.24% increase from ¥166,546,887.92 in the previous year[18]. - The weighted average return on net assets was 6.71%, slightly up from 6.55% in the same period last year[18]. Dividend and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period, nor to increase share capital from capital reserves[77]. Market Position and Competition - The company ranked 15th among the top 100 pharmaceutical wholesale enterprises in China, maintaining its position as the largest pharmaceutical distribution company in Fujian Province for 13 consecutive years[27]. - The retail module of the company entered the top 100 in the "2022-2023 China Pharmacy Value List," ranking 87th[27]. - The company faces a risk of goodwill impairment due to its expansion strategy; if acquired companies do not meet performance expectations, it could significantly affect overall financial performance[72]. - The company is focusing on differentiated business expansion strategies in the medical device procurement sector, adapting to market demand changes[35]. - The company is actively exploring new retail channels and improving its O2O and B2C operational capabilities[36]. Operational Efficiency and Cost Management - The cost of goods sold increased by 7.68% to ¥9,281,898,532.66 from ¥8,620,234,602.90, indicating a rise in operational expenses[48]. - The company's pharmaceutical distribution business grew by 6.05% during the reporting period[35]. - The company's inventory decreased by 1.70% to ¥2,288,408,504.08 from ¥2,548,589,433.26, indicating improved inventory management[55]. - The company has implemented a new "dual control" management system to enhance capital efficiency and risk management[35]. - The company is enhancing its supply chain management capabilities to meet the needs of upstream suppliers and downstream customers[42]. Research and Development - Research and development expenses rose by 38.41% to ¥1,938,212.92, up from ¥1,400,296.54, reflecting increased investment in AI projects[49]. - The company is actively investing in the traditional Chinese medicine (TCM) sector, expanding production capacity and developing a modern TCM production project[33]. - The company is accelerating the construction of modern Chinese medicine production projects and enhancing R&D investment to expand product variety and production capacity[37]. - The company has allocated 8,000 million for research and development in 2023, emphasizing innovation in medical devices[102]. - Research and development expenses increased by 12% in the first half of 2023, totaling 914.36 million, reflecting the company's commitment to innovation[103]. Legal and Regulatory Matters - The company has not faced any significant litigation or arbitration matters during the reporting period[88]. - The company has ongoing litigation involving 34 cases with a total amount of 77.72 million yuan, of which 25 cases have been resolved in favor of the company, recovering 1.67 million yuan[90]. - The company has initiated litigation against Chengdu Hechuang for a total compensation claim of CNY 23.1 million, with a separate claim of CNY 20 million for damages[125]. Future Outlook and Guidance - The company has provided a positive outlook for the remainder of 2023, projecting a revenue growth of approximately 15%[104]. - The company has set a performance guidance of 4,000 million in revenue for the full year 2023, indicating strong confidence in market demand[104]. - Future guidance for 2023 indicates expected revenue growth of 8% to 10%, with projected total revenue between 3,000 million and 3,300 million[103]. - The company plans to expand its market presence by entering three new regions by the end of 2023, aiming for a 10% market share in these areas[104]. Corporate Governance and Compliance - The financial statements were approved by the board of directors on August 4, 2023, indicating a commitment to transparency and regulatory compliance[183]. - The company has established a corporate governance structure that includes a shareholders' meeting, board of directors, and supervisory board[181]. - The company adheres to the accounting standards set forth by the Chinese regulatory authorities, ensuring the accuracy and completeness of its financial reporting[189].

证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 编号：2023-009 √特定对象调研 □分析师会议 投资者关系 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 √现场参观 □其他（请文字说明其他活动内容） 参与单位名称 及人员姓名 国信证券 时间 2023 年 6 月 21 日 9:30-12:00 地点 鹭燕医药会议室 上市公司 接待人员姓名 董事会秘书叶泉青、证券事务代表阮翠婷 一、介绍公司基本概况、业务布局。 二、沟通交流环节 1、公司分销模块现阶段的布局情况及未来发展的规划？ 答：公司现阶段的业务模式以纯销为主，于2009年实现了对 福建省二级以上医疗机构100%覆盖；经过多年深耕以县级医院为 龙头的农村三级医疗卫生服务网，销售终端已覆盖各级医院、卫 生站、诊所及终端药店，并完成了电子商务平台销售渠道的搭建。 投资者关系活 动主要内容介 绍 此外，公司通过并购扩张，在四川、江西、海南三省布局医 药分销业务，在四川、江西、海南三省二级以上公立医疗机构的 覆盖率超95%。未来公司将继续做好"三个能力"建设，即药事 服务能力、准入能力、终端营销能力等， ...

证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 编号：2023-008 √特定对象调研 □分析师会议 投资者关系 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 √现场参观 □其他（请文字说明其他活动内容） 兴业证券、相聚资本、安信基金、富荣基金、长城基金、深圳私 参与单位名称 及人员姓名 享、嘉实基金、申万菱信基金、华夏久盈资产、东方红、大成基 金、诺德基金、合众资产、广发资管等 14 家机构。 时间 2023 年 6 月 15 日 10:00-12:00 地点 会议室 上市公司 接待人员姓名 董事会秘书叶泉青、证券事务代表阮翠婷 一、介绍公司基本概况、业务布局。 二、沟通交流环节 1、亳州中药饮片厂年产值及未来规划？目前建设进度如 何？ 答：中药饮片的市场，未来会同西药的趋势一样。集采的品 种和规模越来越大。刚结束的中药饮片省际联盟集采就是这个趋 投资者关系活 动主要内容介 绍 势的反映。随着中药饮片的监管越来越严、市场越来越规范，市 场中原有的小生产企业生存压力变大，有规模效应、管理规范的 生产企业将获得更大的市场份额。 目前公司下属二家中药饮片生产 ...

Business Overview and Revenue Distribution - In 2022, the company achieved approximately 14 billion yuan in revenue in Fujian Province, 3 billion yuan in Sichuan Province, 2 billion yuan in Jiangxi Province, and 500 million yuan in Hainan Province [2] - Fujian Province accounts for the majority of the company's revenue, but there is still room for growth in various cities within the province [2] - The company's market share outside Fujian Province is relatively small, but it is expected to grow significantly due to ongoing healthcare reforms and centralized procurement policies [2] Profitability and Market Trends - The gross profit margin in Fujian Province is 7%, while it is 9% outside Fujian Province, primarily due to stricter healthcare reforms and lower capital occupation in Fujian [3] - The company expects the market concentration in the pharmaceutical distribution industry to increase significantly as healthcare reforms and centralized procurement policies are implemented nationwide [3] - The company believes that the core goal of healthcare reform is to eliminate unreasonable factors in the pharmaceutical distribution process, which will lead to shorter distribution channels and reduced costs [3] Competitive Advantages and Future Strategies - The company has achieved full coverage of medical institutions in Fujian Province and has core competitiveness in responding to market demands and providing customer service [3] - The company plans to focus on building three key capabilities: pharmaceutical service capability, market access capability, and terminal marketing capability [3] - The company's retail pharmacy business will focus on refined management and operational efficiency, with no strict targets for store expansion but potential mergers and acquisitions to accelerate growth [4] - The company has a competitive advantage in the Fujian market due to its brand effect and integrated wholesale-retail model [4] Expansion and Innovation - The company has successfully expanded into Sichuan, Jiangxi, and Hainan through mergers and acquisitions, with the main challenge being the long accounts receivable period outside Fujian Province [5] - The company plans to deepen its market penetration in these regions and focus on strengthening its retail and innovative business operations [5] - The company is developing AI-based medical devices, including dynamic ECG recorders, fetal heart monitoring systems, and AI-assisted cardiac ultrasound image diagnosis systems, which are currently in the commercialization phase [4] Industrial and Medical Equipment Business - The company's industrial segment focuses on the production and sales of traditional Chinese medicine (TCM) decoction pieces, with plans to potentially expand into TCM formula granules in the future [4] - The company expects significant growth in its industrial segment as it expands its service areas and increases production capacity [4] - The medical equipment distribution sector is expected to follow the same trend as pharmaceuticals, with further deepening of centralized procurement and increased market concentration [4]

证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 编号：2023-006 √特定对象调研 □分析师会议 投资者关系 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称 及人员姓名 兴业证券王声亮、涂磊 时间 2023 年 6 月 6 日 15:00-16:00 地点 鹭燕医药会议室 上市公司 接待人员姓名 董事会秘书叶泉青、证券事务代表阮翠婷 一、介绍公司基本概况、业务布局。 二、沟通交流环节 1、医药流通行业中，国企、民企各有什么竞争优势，未来 的行业格局如何？ 答：国企的优势主要体现在资源、政策扶持方面。而民企机 制灵活，对市场反馈迅速、精细化管理等方面更强。国企和民企 能够对客户的需求提供差异化服务。对于医药流通领域来说，具 投资者关系活 动主要内容介 绍 有全国网络优势的巨头与区域的龙头并存的格局仍然将持续存 在。 2、公司在四川、江西省的市场占有率情况？ 答：公司在四川、江西省目前已基本完成分销网络布局，后 续将持续深耕市场，提升市场占有率。 3、应收账款回款情况是否有变化？四川、江西应收账款 ...